Fig. 1

Structural integrity of BAF complex is essential for neuroblastoma proliferation. A Mass spectrometry analysis of mSWI/SNF complexes composition in SK-N-BE(2) and SH-SY5Y neuroblastoma cell lines. Proteins enriched in BRG1/SMARCA4 co-immunoprecipitation compared with normal IgG control in both cell lines (Bayesian False Discovery Rate (BDFR) < 0.05) are shown. Fold change of average spectrum counts with respect to IgG (FC vs IgG) is represented. B Degradation of mSWI/SNF ATPase subunits in neuroblastoma cells. Upper panel, schematic representation of the catalytic subunits BRM/SMARCA2 and BRG1/SMARCA4. Lower panel, proliferation assay of neuroblastoma cell lines treated with 1 μM of the BRM/BRG1 degrader ACBI1, or its negative control cis-ACBI1 for 96 h. C Protein expression analysis of mSWI/SNF subunits in neuroblastoma cells treated with 1 μM cis-ACBI1 (labelled as –) or ACBI1 (labelled as +) for 96 h. BRM analysis was performed on nuclear extracts, using HDAC1 as nuclear loading control. D mSWI/SNF subtypes specific disruption in neuroblastoma cells. Upper panel, schematic representation of the key subtype-specific subunits selected for gene silencing. Lower panel, 96 h proliferation assays with neuroblastoma cell lines seeded at 72 h post-transduction with shRNA against the indicated genes or with a non-silencing shRNA control. For BRD9 degradation, cells were treated with the dBRD9 degrader or vehicle at the indicated doses. E Protein expression analysis of mSWI/SNF subunits in neuroblastoma cells transduced with shRNA or treated with dBRD9 for 96 h. AR1A means ARID1A; AR1B means ARID1B. *** means p < 0.001. Colour code indicates the condition against which the multiple comparison statistical tests are calculated